A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.
暂无分享，去创建一个
A. Rademaker | R. Stupp | C. Horbinski | A. Sonabend | A. Stegh | C. Ko | R. Lukas | Karan S Dixit | Kathleen McCortney | P. Kumthekar | M. Schwartz | Laura Sharp | C. H. Ko